Date: 2014-02-05
Type of information: Financing round
Company: Anergis (Switzerland)
Investors: Sunstone Capital (Denmark), BioMedInvest (Switzerland), Renaissance PME/Vinci Capital (Switzerland)
Amount: CHF 8 million (€6.5 million)
Funding type: financing round
Planned used: Anergis will use the proceeds to further advance the clinical development of its lead product AllerT, a vaccine to treat birch pollen allergy, and to advance two additional vaccine candidates against house dust mite and ragweed allergies. For AllerT, the funds will specifically allow the preparation of Phase III trials and the conduct of a long-term efficacy follow-up trial of patients who participated in the recently completed field-based Phase II study. The results from this second follow-up season are expected to be available in the third quarter of 2014.
Others: * On February 5, 2014, Anergis, a company discovering and developing proprietary allergy vaccines, has announced the closing of a financing round totaling CHF 8 million (€6.5 million). The financing was fully subscribed by existing investors and directors and was co-lead by Sunstone Capital, BioMedInvest and Renaissance PME/Vinci Capital. Anergis’ lead-product AllerT, a vaccine to treat birch pollen allergies, is due to enter Phase III clinical development in 2014. Two additional vaccine candidates against ragweed pollen allergies (AllerR) and house dust mite allergies (AllerDM) are in preclinical development.
Anergis has raised over CHF 30 million from Renaissance PME/Vinci Capital, Sunstone Capital, BioMedInvest and other investors, including Esperante Ventures and Initiative Capital Romandie/Defi Gestion.
Therapeutic area: Allergic diseases - Immunological diseases
